This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

Remarkable Antidepressant Augmentation Effect of Raloxifene, a Selective Estrogen Receptor Modulator, in a Partial Responder to Fluvoxamine: A Case Report

Nobuhiro Sugiyama, MD, PhD; Daimei Sasayama, MD; and Naoji Amano, MD, PhD

Published: April 16, 2007

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Although selective serotonin reuptake inhibitors (SSRIs) have a relatively low occurrence of adverse events, some patients cannot tolerate certain adverse reactions to SSRIs, such as nausea and dizziness. In these situations, patients often undergo a protracted course of depression because an effective dose cannot be administrated. We report a recent case of major depressive disorder in which the administration of raloxifene, a selective estrogen receptor modulator (SERM), in addition to a prior small dose of fluvoxamine, resulted in a remarkable improvement leading to a complete remission of depressive symptoms.’ ‹


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 68

Quick Links: Depression (MDD)

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...